XOLREMDI Drug Patent Profile

✉ Email this page to a colleague

When do Xolremdi patents expire, and when can generic versions of Xolremdi launch?

Xolremdi is a drug marketed by X4 Pharms and is included in one NDA. There are six patents protecting this drug.

This drug has forty-seven patent family members in eighteen countries.

The generic ingredient in XOLREMDI is mavorixafor. One supplier is listed for this compound. Additional details are available on the mavorixafor profile page.

DrugPatentWatch^® Generic Entry Outlook for Xolremdi

Xolremdi will be eligible for patent challenges on April 26, 2028. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be April 26, 2031. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

Subscribe

AI Research Assistant

Questions you can ask:

What is the 5 year forecast for XOLREMDI?
What are the global sales for XOLREMDI?
What is Average Wholesale Price for XOLREMDI?

Summary for XOLREMDI

International Patents:	47
US Patents:	6
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Patent Applications:	261
What excipients (inactive ingredients) are in XOLREMDI?	XOLREMDI excipients list
DailyMed Link:	XOLREMDI at DailyMed

Drug patent expirations by year for XOLREMDI

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for XOLREMDI

Generic Entry Date for XOLREMDI^: ⤷ Subscribe* Constraining patent/regulatory exclusivity: TO INCREASE THE NUMBER OF CIRCULATING MATURE NEUTROPHILS AND LYMPHOCYTES IN PATIENTS 12 YEARS OF AGE AND OLDER WITH WHIM SYNDROME (WARTS, HYPOGAMMAGLOBULINEMIA, INFECTIONS AND MYELOKATHEXIS) NDA: 218709 Dosage: CAPSULE;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for XOLREMDI

XOLREMDI is protected by six US patents and two FDA Regulatory Exclusivities.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of XOLREMDI is ⤷ Subscribe.

This potential generic entry date is based on TO INCREASE THE NUMBER OF CIRCULATING MATURE NEUTROPHILS AND LYMPHOCYTES IN PATIENTS 12 YEARS OF AGE AND OLDER WITH WHIM SYNDROME (WARTS, HYPOGAMMAGLOBULINEMIA, INFECTIONS AND MYELOKATHEXIS).
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting XOLREMDI

Compositions of CXCR4 inhibitors and methods of preparation and use
Patent Number: ⤷ Subscribe
Patent Expiration: ⤷ Subscribe

Methods for treating immunodeficiency disease
Patent Number: ⤷ Subscribe
Patent Expiration: ⤷ Subscribe
Patented Use: TREATMENT OF PATIENTS 12 YEARS AND OLDER WITH WARTS, HYPOGAMMAGLOBULINEMIA, INFECTIONS, AND MYELOKATHEXIS (WHIM) SYNDROME

Methods for treating cancer
Patent Number: ⤷ Subscribe
Patent Expiration: ⤷ Subscribe

Compositions of CXCR4 inhibitors and methods of preparation and use
Patent Number: ⤷ Subscribe
Patent Expiration: ⤷ Subscribe

Patent Number: ⤷ Subscribe
Patent Expiration: ⤷ Subscribe

FDA Regulatory Exclusivity protecting XOLREMDI

TO INCREASE THE NUMBER OF CIRCULATING MATURE NEUTROPHILS AND LYMPHOCYTES IN PATIENTS 12 YEARS OF AGE AND OLDER WITH WHIM SYNDROME (WARTS, HYPOGAMMAGLOBULINEMIA, INFECTIONS AND MYELOKATHEXIS)
Exclusivity Expiration: ⤷ Subscribe

NEW CHEMICAL ENTITY
Exclusivity Expiration: ⤷ Subscribe

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
X4 Pharms	XOLREMDI	mavorixafor	CAPSULE;ORAL	218709-001	Apr 26, 2024		RX	Yes	Yes	⤷ Subscribe	⤷ Subscribe				⤷ Subscribe
X4 Pharms	XOLREMDI	mavorixafor	CAPSULE;ORAL	218709-001	Apr 26, 2024		RX	Yes	Yes	⤷ Subscribe	⤷ Subscribe				⤷ Subscribe
X4 Pharms	XOLREMDI	mavorixafor	CAPSULE;ORAL	218709-001	Apr 26, 2024		RX	Yes	Yes	⤷ Subscribe	⤷ Subscribe	Y			⤷ Subscribe
X4 Pharms	XOLREMDI	mavorixafor	CAPSULE;ORAL	218709-001	Apr 26, 2024		RX	Yes	Yes	⤷ Subscribe	⤷ Subscribe				⤷ Subscribe
X4 Pharms	XOLREMDI	mavorixafor	CAPSULE;ORAL	218709-001	Apr 26, 2024		RX	Yes	Yes	⤷ Subscribe	⤷ Subscribe				⤷ Subscribe
X4 Pharms	XOLREMDI	mavorixafor	CAPSULE;ORAL	218709-001	Apr 26, 2024		RX	Yes	Yes	⤷ Subscribe	⤷ Subscribe	Y			⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

International Patents for XOLREMDI

See the table below for patents covering XOLREMDI around the world.

Subscribe to access the full database, or Subscribe
Country	Patent Number	Title	Estimated Expiration
Israel	281082	תכשירים של מעכבי cxcr4 ושיטות להכנה ושימוש (Compositions of cxcr4 inhibitors and methods of preparation and use)	⤷ Subscribe
European Patent Office	3843720	COMPOSITIONS D'INHIBITEURS DE CXCR4 ET MÉTHODES DE PRÉPARATION ET D'UTILISATION (COMPOSITIONS OF CXCR4 INHIBITORS AND METHODS OF PREPARATION AND USE)	⤷ Subscribe
Slovenia	3393468		⤷ Subscribe
Spain	2935834		⤷ Subscribe
Japan	2021535146	ＣＸＣＲ４阻害剤の組成物ならびに調製および使用の方法	⤷ Subscribe
Eurasian Patent Organization	202190377	КОМПОЗИЦИИ ИНГИБИТОРОВ CXCR4 И СПОСОБЫ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ	⤷ Subscribe
>Country	>Patent Number	>Title	>Estimated Expiration